Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 47
1.
Clin Pharmacokinet ; 63(4): 551-560, 2024 Apr.
Article En | MEDLINE | ID: mdl-38504082

BACKGROUND: Sodium zirconium cyclosilicate (SZC) is an approved oral treatment for hyperkalemia that selectively binds potassium (K+) in the gastrointestinal tract and removes K+ from the body through increased fecal excretion. Here, we describe the population pharmacodynamic (PopPD) response of serum K+ concentration in patients with hyperkalemia who are treated with SZC, estimate the impact of patients' intrinsic and extrinsic factors, and compare predicted serum K+ responses between 5 g alternate daily (QOD) and 2.5 g once daily (QD) maintenance doses. METHODS: PopPD analysis was based on pooled data from seven phase II and III clinical trials for SZC. A semi-mechanistic longitudinal mixed-effects (base) model was used to characterize serum K+ concentration after SZC dosing. Indirect-response, virtual pharmacokinetics-pharmacodynamics (PK-PD) modeling was used to mimic the drug exposure compartment. Full covariate modeling was used to assess covariate impact on the half-maximal effective concentration of drug (EC50), placebo response, and Kout. Models were evaluated using goodness-of-fit plots, relative standard errors, and visual predictive checks, and data were stratified to optimize model performance across subgroups. Covariate effects were evaluated based on the magnitude of change in serum K+ between baseline and end of correction phase dosing (48 h, SZC 10 g three times a day) and maintenance phase dosing (28 days, SZC 10 g QD) using a reference subject. RESULTS: The analysis data set included 2369 patients and 25,764 serum K+ observations. The mean (standard deviation) patient age was 66.0 (12) years, 61% were male, 68% were White, 34% had congestive heart failure, and 62% had diabetes. Mean (standard deviation) serum K+ at baseline was 5.49 (0.43) mmol/L. Both the base and full covariance models adequately described observed data. In the final model, there was a sigmoid exposure response on Kin, with EC50 of 32.8 g and a Hill coefficient of 1.36. The predicted placebo-adjusted dose-responses of serum K+ change appeared nearly linear in the correction and maintenance phases. No clinically meaningful difference in placebo-adjusted serum K+ change from baseline at 28 days was observed between maintenance regimens of SZC 5 g QOD and 2.5 g QD. A greater SZC treatment response was associated with high serum K+ at baseline, advanced age, lower body weight, lower estimated glomerular filtration rate, and Black/African American and Asian race, compared with the reference patient. The impact of heart failure status and diabetes status was only minor. CONCLUSIONS: The PopPD model of SZC adequately described changes in serum K+ concentration during correction and maintenance phase dosing. A greater treatment response was associated with various covariates, but the impact of each was modest. Overall, these findings suggest that no adjustment in SZC dose is needed for any of the covariates evaluated.


Dose-Response Relationship, Drug , Hyperkalemia , Models, Biological , Potassium , Silicates , Adult , Aged , Female , Humans , Male , Middle Aged , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Hyperkalemia/blood , Hyperkalemia/drug therapy , Potassium/blood , Silicates/administration & dosage , Silicates/pharmacokinetics
2.
Int J Biol Macromol ; 171: 514-526, 2021 Feb 28.
Article En | MEDLINE | ID: mdl-33428954

The Alginate-Neusilin US2 micro-composite (MC) beads were fabricated and optimized for oral delivery of hesperidin (HES). A 32 full factorial design encompassing independent variables (factors) such as the concentration of sodium alginate (X1), and Neusilin US2 (X2) and dependant variables (response) such as particle size (Y1), entrapment efficiency (Y2), and swelling degree (Y3). Nine batches were prepared by formulation design employing statistical software JMP 13.2.1. The multiple regression analysis (MLRA) was carried to explore the influence of factor over responses. Further, a prediction profiler was used to trace the optimum concentration of factors based on desirable responses. The optimized beads (OF) were characterized for their morphology and size by motic microscopy and scanning electron microscopy. In vitro release, kinetic studies were performed in simulated gastric and intestinal fluids. In vivo pharmacokinetic studies revealed better absorption of HES from optimized beads (OF) compared to HES suspension which could be due to the prevention of acidic degradation of HES in the stomach. The estimated shelf life of OF formulation was found to be 3.86 years suggested better stability after fabrication. In a nutshell, the developed micro-composite beads of HES could be a better alternative for promising oral sustained delivery of HES.


Alginates/chemistry , Aluminum Compounds/chemistry , Drug Carriers/chemistry , Gastric Juice/metabolism , Hesperidin/administration & dosage , Magnesium Compounds/chemistry , Silicates/chemistry , Administration, Oral , Alginates/administration & dosage , Alginates/pharmacokinetics , Aluminum Compounds/administration & dosage , Aluminum Compounds/pharmacokinetics , Animals , Body Fluids/metabolism , Chemistry Techniques, Analytical , Drug Carriers/administration & dosage , Drug Carriers/pharmacokinetics , Drug Compounding , Drug Liberation , Drug Stability , Hesperidin/pharmacokinetics , Intestines , Kinetics , Magnesium Compounds/administration & dosage , Magnesium Compounds/pharmacokinetics , Male , Microscopy, Electron, Scanning , Microspheres , Particle Size , Rats, Wistar , Silicates/administration & dosage , Silicates/pharmacokinetics
3.
J Nanobiotechnology ; 18(1): 104, 2020 Jul 25.
Article En | MEDLINE | ID: mdl-32711522

This study aimed to develop a ternary nanocomposite system of organoclay, glycol-chitosan, and Eudragit®S100 as an effective colon targeted drug delivery carrier to enhance the oral absorption of insulin. A nanocomplex of insulin and aminoclay was prepared via spontaneous co-assembly, which was then coated with glycol-chitosan and Eudragit S®100 (EGAC-Ins). The double coated nanocomplex, EGAC-Ins demonstrated a high entrapment efficiency of greater than 90% and a pH-dependent drug release. The conformational stability of insulin entrapped in EGAC-Ins was effectively maintained in the presence of proteolytic enzymes. When compared to a free insulin solution, EGAC-Ins enhanced drug permeability by approximately sevenfold in Caco-2 cells and enhanced colonic drug absorption in rats. Accordingly, oral EGAC-Ins significantly reduced blood glucose levels in diabetic rats while the hypoglycemic effect of an oral insulin solution was negligible. In conclusion, EGAC-Ins should be a promising colonic delivery system for improving the oral absorption of insulin.


Colon , Drug Carriers , Insulin , Nanocomposites/chemistry , Administration, Oral , Animals , Caco-2 Cells , Chitosan/chemistry , Chitosan/pharmacokinetics , Colon/chemistry , Colon/metabolism , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Humans , Insulin/administration & dosage , Insulin/chemistry , Insulin/pharmacokinetics , Male , Polymethacrylic Acids/chemistry , Polymethacrylic Acids/pharmacokinetics , Rats , Rats, Wistar , Silicates/chemistry , Silicates/pharmacokinetics
4.
ACS Appl Mater Interfaces ; 12(22): 24644-24654, 2020 Jun 03.
Article En | MEDLINE | ID: mdl-32407072

Recently, Mn(II)-based T1-weighted magnetic resonance imaging (MRI) contrast agents (CAs) have been explored widely for cancer diagnosis. However, the "always-on" properties and poor excretability of the conventional Mn(II)-based CAs leads to high background signals and unsatisfactory clearance from the body. Here, we report an "in situ three-dimensional to two-dimensional (3D-to-2D) transformation" method to prepare novel excretable 2D manganese-based layered silicates (Mn-LSNs) with extremely high signal-to-noise for tumor-specific MR imaging for the first time. Our observations combined with density functional theory (DFT) calculations reveal that 3D metal (Mn, Fe, Co) oxide nanoparticles are initially formed from the molecular precursor solution and then in situ transform into 2D metal (Mn, Fe, Co)-based layered silicates triggered by the addition of tetraethyl orthosilicate, which provides a time-saving and versatile way to prepare novel 2D silicate nanomaterials. The unique ion-exchangeable capacity and high host layer charge density endow Mn-LSNs with an "ON/OFF" pH/GSH stimuli-activatable T1 relaxivity with superb high signal-to-noise (640-, 1200-fold for slightly acidic and reductive changes, respectively). Further in vivo MR imaging reveals that Mn-LSNs exhibit a continuously rapid T1-MRI signal enhancement in tumor tissue and no visible signal enhancement in normal tissue, indicating an excellent tumor-specific imaging. In addition, Mn-LSNs exhibit a rapid excretion from the mouse body in 24 h and invisible organ toxicity, which could help to solve the critical intractable degradation issue of conventional inorganic CAs. Moreover, the tumor microenvironment (pH/GSH/H2O2) specific degradability of Mn-LSNs could help to improve the penetration depth of particles into the tumor parenchyma. Developing this novel Mn-LSNs contrast agent, together with the already demonstrated capacity of layered silicates for drug and gene delivery, provides opportunities for future cancer theranostics.


Contrast Media/pharmacology , Metal Nanoparticles/chemistry , Neoplasms/diagnostic imaging , Silicates/pharmacology , Animals , Cell Line, Tumor , Contrast Media/pharmacokinetics , Contrast Media/toxicity , Density Functional Theory , Humans , Magnetic Resonance Imaging , Manganese/chemistry , Metal Nanoparticles/toxicity , Mice, Inbred BALB C , Models, Chemical , Silicates/pharmacokinetics , Silicates/toxicity
5.
Daru ; 28(1): 191-208, 2020 Jun.
Article En | MEDLINE | ID: mdl-32034683

AIM: Canagliflozin (CFZ), a novel SGLT II antagonist, exhibits erratic absorption after oral administration. The current study entails development and evaluation of spray dried lipid based formulation (solid SMEDDS) for enhancing oral bioavailability and anti-diabetic activity of CFZ. METHODS: Solid SMEDDS developed through spray drying containing Neusilin US2 as an adsorbent. The formed solid SMEDDS were characterized for physicochemical and solid state attributes. Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) were used to confirm the spherical morphology. In vitro dissolution, ex vivo permeability and in vivo pharmacokinetic studies were conducted to determine the release rate, permeation rate and absorption profile of CFZ, respectively. Pharmacodynamic studies were done as per standard protocols. RESULTS: The optimized solid SMEDDS exhibited acceptable practical yield and flow properties and is vouched with enhanced amorphization, nanoparticulate distribution and acceptable drug content. The spherical morphology of solid SMEDDS and reconstituted SMEDDS were confirmed in SEM and TEM, respectively. In vitro dissolution studies revealed multi-fold release behavior in CFZ in various dissolution media, whereas, remarkable permeability was observed in jejunum segment of rat intestine. Pharmacokinetic studies of CFZ in solid SMEDDS demonstrated 2.53 and 1.43 fold enhancement in Cmax and 2.73 and 1.98 fold in AUC 0-24h, as compared to pure API and marketed formulation, respectively. Pharmacological evaluation of solid SMEDDS revealed enhanced anti-diabetic activity of CFZ through predominant SGLT II inhibition in rats, as evident from evaluation of biochemical levels, urinary glucose excretion studies and SGLT II expression analysis. CONCLUSION: The current work describes significant improvement biopharmaceutical properties of CFZ in solid SMEDD formulation. Graphical abstract Graphical Abstract: Enhanced oral bioavailability and anti-diabetic activity of canagliflozin through a spray dried lipid based oral delivery: a novel paradigm.


Canagliflozin/administration & dosage , Diabetes Mellitus, Experimental/drug therapy , Drug Delivery Systems , Hypoglycemic Agents/administration & dosage , Administration, Oral , Aluminum Compounds/administration & dosage , Aluminum Compounds/chemistry , Aluminum Compounds/pharmacokinetics , Animals , Biological Availability , Canagliflozin/blood , Canagliflozin/chemistry , Canagliflozin/pharmacokinetics , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/urine , Drug Liberation , Glycosuria , Hypoglycemic Agents/blood , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacokinetics , Intestinal Absorption , Kidney/drug effects , Kidney/metabolism , Lipids/administration & dosage , Lipids/chemistry , Lipids/pharmacokinetics , Magnesium Compounds/administration & dosage , Magnesium Compounds/chemistry , Magnesium Compounds/pharmacokinetics , Pharmaceutic Aids/administration & dosage , Pharmaceutic Aids/chemistry , Pharmaceutic Aids/pharmacokinetics , Rats, Wistar , Silicates/administration & dosage , Silicates/chemistry , Silicates/pharmacokinetics , Sodium-Glucose Transporter 2/metabolism , Spray Drying
6.
ACS Infect Dis ; 5(9): 1634-1644, 2019 09 13.
Article En | MEDLINE | ID: mdl-31309823

Fusidic acid (FA), a natural product fusidane triterpene-based antibiotic with unique structural features, is active in vitro against Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). While possessing good pharmacokinetics in man, FA is rapidly metabolized in rodents, thus complicating proof-of-concept studies in this model. Toward the repositioning of FA as an anti-TB agent, we herein describe the synthesis, activity, and metabolism of FA and semisynthesized ester derivatives in rat liver microsomes, rat plasma, and mycobacterial cell culture. FA and derivative molecules with a free C-3 OH underwent species-specific metabolism to the corresponding 3-OH epimer, 3-epifusidic acid (3-epiFA). FA was also metabolized in rat plasma to form FA lactone. These additional routes of metabolism may contribute to the more rapid clearance of FA observed in rodents. C-3 alkyl and aryl esters functioned as classic prodrugs of FA, being hydrolyzed to FA in microsomes, plasma, and Mycobacterium tuberculosis culture. In contrast, C-3 silicate esters and C-21 esters were inert to hydrolysis and so did not act as prodrugs. The antimycobacterial activity of the C-3 silicate esters was comparable to that of FA, and these compounds were stable in microsomes and plasma, identifying them as potential candidates for evaluation in a rodent model of tuberculosis.


Esters/chemical synthesis , Fusidic Acid/chemistry , Mycobacterium tuberculosis/growth & development , Silicates/chemical synthesis , Animals , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Bacteriological Techniques , CHO Cells , Cricetulus , Drug Repositioning , Esters/chemistry , Esters/pharmacokinetics , Esters/pharmacology , Microsomes, Liver/chemistry , Mycobacterium tuberculosis/drug effects , Plasma/chemistry , Rats , Silicates/chemistry , Silicates/pharmacokinetics , Silicates/pharmacology
7.
Dent Med Probl ; 56(2): 161-165, 2019.
Article En | MEDLINE | ID: mdl-31274254

BACKGROUND: Endodontic sealers are essential for sealing gutta-percha to the dentin walls. They help to ensure that the canal remains free of microorganisms which might lead to infection. In order to perform their intended function, the sealers should properly adhere to the dentin walls and remain insoluble when set in the canal. OBJECTIVES: The purpose of this study was to evaluate the bond strength and solubility of a novel polydimethylsiloxane-gutta-percha calcium silicate-containing root canal sealer (GuttaFlow® bioseal) and compare it with the zinc oxide and eugenol sealer (Zical®). MATERIAL AND METHODS: The endodontic sealers used in this study were GuttaFlow bioseal and Zical. The bond strength was assessed using push-out bond strength test in 3 root segments: coronal, middle and apical. The solubility was tested according to the American National Standards Institute / American Dental Association (ANSI/ADA) specification No. 57 at 3 different time intervals: 1, 7 and 14 days. RESULTS: The push-out bond strength in all root segments was significantly higher in Zical compared to GuttaFlow bioseal. The solubility was significantly higher on day 1 and 7 in Zical compared to GuttaFlow bioseal, and on day 14, the difference between them was not significant. CONCLUSIONS: Within the limitations of this study, the endodontic sealer GuttaFlow bioseal showed low bond strength values compared to Zical. The solubility of the set GuttaFlow bioseal and Zical were both within the recommended ANSI/ADA levels.


Calcium Compounds , Gutta-Percha , Root Canal Filling Materials , Silicates , Calcium Compounds/pharmacokinetics , Calcium Compounds/pharmacology , Dental Pulp Cavity , Dimethylpolysiloxanes , Epoxy Resins , Gutta-Percha/pharmacokinetics , Gutta-Percha/pharmacology , Root Canal Filling Materials/pharmacokinetics , Root Canal Filling Materials/pharmacology , Silicates/pharmacokinetics , Silicates/pharmacology , Solubility , United States
8.
Mater Sci Eng C Mater Biol Appl ; 103: 109833, 2019 Oct.
Article En | MEDLINE | ID: mdl-31349499

The different lineage-specific biological properties of articular cartilage and subchondral bone present a great challenge in the construction of bi-lineage scaffolds for simultaneous osteochondral regeneration. To overcome this challenge, strontium incorporated calcium silicate (Sr-CS) ceramic was prepared for bi-lineage formation of scaffolds in this study. The positive result of Sr-CS in the regeneration of osteochondral defects was first proven by its improved effect on the osteogenesis and chondrogenesis induction of mesenchymal stem cells (MSCs). After that, scaffold-mediated macrophage polarization between classically activated inflammatory macrophages (termed M1Ф) and alternatively activated inflammatory macrophages (termed M2Ф) was assayed to investigate whether the incorporation of Sr into calcium silicate could alter host-to-scaffold immune response. Furthermore, the interactions between Sr-CS pretreated macrophages and MSCs differentiation were performed to prove the enhancement effect of suppressed inflammatory response on osteogenesis and chondrogenesis. In vivo transplantation showed that the Sr-CS scaffolds distinctly improved the regeneration of cartilage and subchondral bone, as compared to the calcium silicate scaffolds. On the one hand, the mechanism attributes to enhancement of strontium on the osteogenic and chondrogenic differentiation of MSCs. On the other hand, the reason can partially be attributed to suppressed synovial inflammatory response, which has improved effects on enhancement of osteogenesis and chondrogenesis. These findings suggest that monophasic Sr-CS scaffolds with a bi-lineage conducive property and an inflammatory response regulatory property represents a viable strategy for simultaneous regeneration of osteochondral defects.


Chondrogenesis/drug effects , Immunologic Factors , Macrophages/immunology , Mesenchymal Stem Cells/immunology , Osteogenesis/drug effects , Strontium , Tissue Scaffolds/chemistry , Animals , Calcium Compounds/chemistry , Calcium Compounds/pharmacokinetics , Calcium Compounds/pharmacology , Cells, Cultured , Chondrogenesis/immunology , Immunologic Factors/chemistry , Immunologic Factors/pharmacokinetics , Immunologic Factors/pharmacology , Osteogenesis/immunology , Rabbits , Silicates/chemistry , Silicates/pharmacokinetics , Silicates/pharmacology , Strontium/chemistry , Strontium/pharmacokinetics , Strontium/pharmacology
9.
J Biomed Mater Res B Appl Biomater ; 107(6): 2195-2201, 2019 08.
Article En | MEDLINE | ID: mdl-30637978

To evaluate the properties of experimental mineral trioxide aggregate (MTA) resin-modified materials for root-end filling procedures, varying their compositions regarding the addition of hydroxiapatite (HA) or dicalcium phosphate dihydrate, with or without chlorhexidine digluconate. White MTA (Angelus, Londrina, Brazil) was used as a reference material. Degree of conversion (DC) was evaluated by Fourier transformed infrared (FTIr) spectroscopy (n = 5). Flowability (n = 3) and radiopacity (n = 3) were evaluated following ISO 6876:2001 methods. For splitting tensile strength analysis, cylindrical samples (n = 10) were subjected to compressive load using a universal testing machine (Instron Corporation, Norwood, MA). Water sorption and solubility tests were performed according to ISO 4049:2009 methods. Calcium ion release and pH analysis (n = 10) were evaluated using a pH meter (Orion, Watsonville, CA). Cytotoxicity (n = 8) of materials extracts was evaluated as cell viability percentage. Statistical analysis was performed using Kolmogorov-Smirnov for normal distribution and data was subjected to one-way ANOVA and Tukey test (α = 0.05). Addition of chlorhexidine digluconate reduced DC mean values for experimental materials (<50%). White MTA demonstrated lower flowability (5.3 mm) and higher radiopacity (9.8 mm Al), splitting tensile strength (9.1 MPa), solubility (8.2 µg/mm3 ), calcium ion release (~26.5 ppm), cytotoxicity (55.2%), and pH mean values (10.8), when compared to experimental materials. All groups demonstrated a decrease in calcium release (<85%) and pH (<13%). Formulation containing HA demonstrated similar pH values after 28 days when compared to white MTA. Evaluated experimental resin-modified MTA based materials without chlorhexidine digluconate showed satisfactory results for all physico-chemical properties tested and cytotoxicity. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B: 2195-2201, 2019.


Aluminum Compounds , Calcium Compounds , Chlorhexidine/analogs & derivatives , Fibroblasts/metabolism , Materials Testing , Oxides , Root Canal Filling Materials , Silicates , Aluminum Compounds/chemistry , Aluminum Compounds/pharmacokinetics , Aluminum Compounds/pharmacology , Animals , Calcium Compounds/chemistry , Calcium Compounds/pharmacokinetics , Calcium Compounds/pharmacology , Cell Line , Chlorhexidine/chemistry , Chlorhexidine/pharmacokinetics , Chlorhexidine/pharmacology , Drug Combinations , Mice , Oxides/chemistry , Oxides/pharmacokinetics , Oxides/pharmacology , Root Canal Filling Materials/chemistry , Root Canal Filling Materials/pharmacokinetics , Root Canal Filling Materials/pharmacology , Silicates/chemistry , Silicates/pharmacokinetics , Silicates/pharmacology
10.
Eur J Pharm Sci ; 130: 44-53, 2019 Mar 15.
Article En | MEDLINE | ID: mdl-30660800

The magadiite (MAG) was modified by cetyltrimethyl ammonium-Bromide (CTAB) and then further modified by Chitosan (CS) which is called organic modified-magadiite as magadiite-cetyltrimethyl ammonium bromide (MAG-CTAB) and magadiite-cetyltrimethyl ammonium bromide-Chitosan (MAG-CTAB-CS), respectively, in this research study. The MAG, MAG-CTAB, and MAG-CTAB-CS were used as 5-Fluorouracil (5-FU) drug carrier materials; the drug carrier's materials were marked as magadiite-5-Fluorouracil (MAG/5-FU), magadiite-cetyltrimethyl ammonium bromide-5-Fluorouracil (MAG-CTAB/5-FU), and magadiite-cetyltrimethyl ammonium bromide-Chitosan (MAG-CTAB-CS/5-FU). X-ray diffraction(XRD, Flourier transform infrared spectrometry (FTIR) and scanning electron microscopy (SEM) results were shown that 5-Fluorouracil was combined with carrier materials through physical apparent adsorption, ion exchange, chemical bond, hydrogen bond, and electrostatic interaction. The drug carriers in vitro release behavior in simulated gastric fluids (SGF,pH = 1.35) and intestinal fluids (SIF,pH = 7.40) were investigated. The drug loading capacity and accumulated release ration were as follows the order: MAG-CTAB-CS/5-FU > MAG-CTAB/5-FU > MAG/5-FU. The drug loading capacity of MAG-CTAB-CS/5-FU was 162.29 mg/g, 48 h later the drug accumulated release ratio was 61.24%, and the release amount was 97.52 mg/g for 24 h. Korsmeyer-Peppas model and First order model were found to be suitable to describe the vitro release behavior of 5-Fluorouracil. This would be an economically viable and efficient method for the preparation of advanced drug delivery system.


Antimetabolites, Antineoplastic/pharmacokinetics , Drug Carriers/pharmacokinetics , Drug Liberation , Fluorouracil/pharmacokinetics , Silicates/pharmacokinetics , Antimetabolites, Antineoplastic/chemistry , Drug Carriers/chemistry , Fluorouracil/chemistry , Silicates/chemistry , Spectroscopy, Fourier Transform Infrared/methods , X-Ray Diffraction/methods
11.
Microsc Res Tech ; 82(5): 624-629, 2019 May.
Article En | MEDLINE | ID: mdl-30614139

This study investigated the dentinal tubule penetration of mineral trioxide aggregate (MTA), NeoMTA Plus and Biodentine placed by either manual condensation or ultrasonic activation in simulated open apex model. Standardized divergent open apex models were created using palatal roots of 60 human maxillary molars and divided into six groups according to the used cements and activation methods (n = 10): MTA-manual condensation, MTA-ultrasonic activation, NeoMTA Plus-manual condensation, NeoMTA Plus-ultrasonic activation, Biodentine-manual condensation, Biodentine-ultrasonic activation. For the measurement of penetration, the cements were mixed with 0.1% Rhodamin B and 6-mm apical portions of each root canal were obturated in an orthograde direction. The roots were embedded into acrylic blocks, and 1-mm-thick sections were obtained at 3 mm from the apex. Specimens were mounted onto glass slides and scanned under a confocal laser scanning microscope (CLSM) and stereomicroscope. Dentinal tubule penetration areas, depth and percentage were measured using LSM and ImageJ software. The data were analyzed using two-way analysis of variance (anova) with Bonferroni correction (α = 0.05). No correlation was found between stereomicroscope and CLSM analyses (p > .05). CLSM analysis showed no significant differences between MTA, NeoMTA Plus, and Biodentine groups when manual condensation was used (p > .05). Ultrasonic activation did not increase the tubular penetration of MTA, NeoMTA Plus or Biodentine as compared to manual condensation of each material (p > .05). MTA, NeoMTA Plus and Biodentine showed similar tubular penetration when manual condensation was used. Ultrasonic activation of these cements had no effect on tubular penetration of each material as compared to the manual condensation counterparts.


Calcium Compounds/radiation effects , Dental Cements/radiation effects , Dental Pulp Cavity/chemistry , Dentin/chemistry , Root Canal Preparation/methods , Silicates/radiation effects , Sonication , Calcium Compounds/pharmacokinetics , Dental Cements/pharmacokinetics , Fluorescent Dyes/administration & dosage , Fluorescent Dyes/analysis , Humans , Image Processing, Computer-Assisted , Microscopy, Confocal , Molar , Rhodamines/administration & dosage , Rhodamines/analysis , Silicates/pharmacokinetics , Staining and Labeling
12.
Pharm Res ; 36(1): 21, 2018 Dec 05.
Article En | MEDLINE | ID: mdl-30519891

PURPOSE: To explore the feasibility of spray dried smectite clay particles fabricated from montmorillonite or laponite materials for adsorbing dietary lipids and reducing rodent weight gain in vivo. METHODS: Spray dried montmorillonite (SD-MMT) and spray dried laponite (SD-LAP) particles were prepared via spray drying. Particle morphology, surface area and redispersion/aggregation properties in aqueous media were characterized. The ability of SD-MMT and SD-LAP particles to inhibit lipid digestion kinetics and adsorb lipid species from solution was assessed during in vitro lipolysis using proton nuclear magnetic resonance analysis. SD-MMT and SD-LAP particles were dosed to rodents fed a high-fat diet and their effect on body weight gain was evaluated. RESULTS: Both SD-MMT and SD-LAP particles adsorbed significant quantities of medium chain triglycerides and lipolytic products from solution during in vitro lipolysis. At a concentration of 50% w/w relative to lipid content, SD-MMT and SD-LAP particles adsorbed 42% and 94% of all lipid species, respectively. SD-MMT and SD-LAP particles also reduced the extent of rodent weight gain relative to the negative control treatment group and performed similarly to orlistat via an alternate mechanism of action. CONCLUSIONS: Spray dried smectite clay particles (SD-MMT and SD-LAP) with significant adsorptive capacities for dietary lipids and digestion products were successfully fabricated. These particles may be developed as novel anti-obesity treatments with fewer adverse effects than currently marketed treatment options.


Bentonite/pharmacology , Obesity/drug therapy , Silicates/pharmacology , Adsorption/drug effects , Animals , Bentonite/chemistry , Bentonite/pharmacokinetics , Body Weight/drug effects , Lipase/metabolism , Lipid Metabolism/drug effects , Lipolysis/drug effects , Male , Nanoparticles/therapeutic use , Obesity/metabolism , Particle Size , Rats , Rats, Sprague-Dawley , Silicates/chemistry , Silicates/pharmacokinetics , Triglycerides/metabolism
13.
Article En | MEDLINE | ID: mdl-29869925

A novel aluminum/olivine composite (AOC) was prepared by wet impregnation followed by calcination and was introduced as an efficient adsorbent for defluoridation. The adsorption of fluoride was modeled with one-, two- and three-parameter isotherm equations by non-linear regression to demonstrate the adsorption equilibrium. The FI was the best-fitted model among the two-parameter isotherms with a R2 value of 0.995. The three-parameter models were found to have better performance with low values of the error functions and high F values. The neural-network-based model was applied for the first time in the isotherm study. The optimized model was framed with eight neurons in hidden layer with a mean square of error of 0.0481 and correlation coefficient greater than 0.999. The neural-based model has the better predictability with a higher F value of 9484 and R2 value of 0.998 compared to regression models, exhibiting the F value and the R2 in the range of 86-3572 and 0.835-0.995, respectively. The material characterization established the formation of the aluminum oxide, silicate, etc. onto the olivine which is conducive of the removal of fluoride by the formation of aluminum fluoride compounds, such as AlF3 in the spent material after defluoridation.


Fluorides/pharmacokinetics , Iron Compounds/pharmacokinetics , Magnesium Compounds/pharmacokinetics , Neural Networks, Computer , Silicates/pharmacokinetics , Water Purification , Absorption, Physicochemical , Aluminum/chemistry , Aluminum/pharmacokinetics , Aluminum Oxide/chemistry , Chemical Phenomena , Fluorides/chemistry , Iron Compounds/chemistry , Kinetics , Least-Squares Analysis , Magnesium Compounds/chemistry , Silicates/chemistry , Temperature , Water Purification/instrumentation , Water Purification/methods
14.
Sci Rep ; 7(1): 8423, 2017 08 21.
Article En | MEDLINE | ID: mdl-28827674

Mesoporous silica nanoparticles (MSNs) are extensively explored as drug delivery systems, but in depth understanding of design-toxicity relationships is still scarce. We used zebrafish (Danio rerio) embryos to study toxicity profiles of differently surface functionalized MSNs. Embryos with the chorion membrane intact, or dechoroniated embryos, were incubated or microinjected with amino (NH2-MSNs), polyethyleneimine (PEI-MSNs), succinic acid (SUCC-MSNs) or polyethyleneglycol (PEG-MSNs) functionalized MSNs. Toxicity was assessed by viability and cardiovascular function. NH2-MSNs, SUCC-MSNs and PEG-MSNs were well tolerated, 50 µg/ml PEI-MSNs induced 100% lethality 48 hours post fertilization (hpf). Dechoroniated embryos were more sensitive and 10 µg/ml PEI-MSNs reduced viability to 5% at 96hpf. Sensitivity to PEG- and SUCC-, but not NH2-MSNs, was also enhanced. Typically cardiovascular toxicity was evident prior to lethality. Confocal microscopy revealed that PEI-MSNs penetrated into the embryos whereas PEG-, NH2- and SUCC-MSNs remained aggregated on the skin surface. Direct exposure of inner organs by microinjecting NH2-MSNs and PEI-MSNs demonstrated that the particles displayed similar toxicity indicating that functionalization affects the toxicity profile by influencing penetrance through biological barriers. The data emphasize the need for careful analyses of toxicity mechanisms in relevant models and constitute an important knowledge step towards the development of safer and sustainable nanotherapies.


Calcium Compounds/toxicity , Membranes/metabolism , Nanoparticles , Permeability , Silicates/toxicity , Surface Properties , Animals , Calcium Compounds/pharmacokinetics , Cardiovascular System/drug effects , Embryo, Nonmammalian , Silicates/pharmacokinetics , Survival Analysis , Zebrafish
15.
Int J Artif Organs ; 40(11): 641-646, 2017 Oct 27.
Article En | MEDLINE | ID: mdl-28708217

INTRODUCTION: The aim of this study was to evaluate and compare the calcium (Ca2+) and hydroxide (OH-) ion release of 4 artificially produced pulp capping materials (MTA, Biodentin, TheraCal LC, Calsimol) used for indirect pulp capping treatment. METHODS: In total, 70 freshly extracted human third molar teeth were used for the study. Cavities of extracted teeth were prepared by round burs. The remaining dentin thickness (1 ± 0.3 mm) tissue was measured by a micrometer and cone beam computerized tomography. Indirect pulp capping was performed in the cavities using Calcimol, MTA, TheraCal LC and Biodentin. The leached Ca2+ were measured using optical emission spectrometry and the release of OH- ions using a pH meter. The measurements were performed after 24 hours, 7 days and 28 days in saline solution. Statistical analysis was performed using 1-way and 2-way analysis of variance (ANOVA) tests (p<0.05). RESULTS: Ca2+ ions were detected in treated saline solution during the experimental period for all materials. All the measurements of Biodentin and Theracal LC levels for Ca2+ ions were higher than those of the other materials (p<0.05). For all materials, Ca2+-ion release increased during the first 7 days followed by a linear decrease during the subsequent study periods. The Biodentine group showed the highest OH- ion rates compared to the other materials in the 24-hour examination period, while the scores gradually decreased during the subsequent measurement periods (p<0.05). CONCLUSIONS: Tricalcium silicate materials such as Biodentine and TheraCal LC used in this study may be preferable for indirect pulp capping because of their stimulation of hard tissue formation and ion-releasing ability.


Calcium/pharmacokinetics , Dental Pulp/metabolism , Hydroxides/pharmacokinetics , Pulp Capping and Pulpectomy Agents/pharmacokinetics , Aluminum Compounds/pharmacokinetics , Calcium Compounds/pharmacokinetics , Calcium Hydroxide/pharmacokinetics , Dental Pulp Capping , Drug Combinations , Humans , Oxides/pharmacokinetics , Resin Cements/pharmacokinetics , Silicates/pharmacokinetics , Tissue Culture Techniques
16.
Mol Nutr Food Res ; 61(2)2017 02.
Article En | MEDLINE | ID: mdl-27670150

SCOPE: Silicon (Si) is one of the most abundant trace elements in the body. Although pharmacokinetics data described its absorption from the diet and its body excretion, the mechanisms involved in the uptake and transport of Si across the gut wall have not been established. METHODS AND RESULTS: Caco-2 cells were used as a well-accepted in vitro model of the human intestinal epithelium to investigate the transport, across the intestinal barrier in both the absorption and excretion directions, of Si supplied as orthosilicic acid stabilized by vanillin complex (OSA-VC). The transport of this species was found proportional to the initial concentration and to the duration of incubation, with absorption and excretion mean rates similar to those of Lucifer yellow, a marker of paracellular diffusion, and increasing in the presence of EGTA, a chelator of divalents cations including calcium. A cellular accumulation of Si, polarized from the apical side of cells, was furthermore detected. CONCLUSION: These results provide evidence that Si, ingested as a food supplement containing OSA-VC, crosses the intestinal mucosa by passive diffusion via the paracellular pathway through the intercellular tight junctions and accumulates intracellularly, probably by an uptake mechanism of facilitated diffusion. This study can help to further understand the kinetic of absorption of Si.


Intestinal Mucosa/metabolism , Silicon/pharmacokinetics , Benzaldehydes/pharmacokinetics , Biological Transport/drug effects , Caco-2 Cells , Dose-Response Relationship, Drug , Egtazic Acid/pharmacology , Humans , Intestinal Mucosa/drug effects , Silicates/pharmacokinetics , Silicic Acid/pharmacokinetics , Silicon/chemistry
17.
Minerva Stomatol ; 65(5): 269-75, 2016 Oct.
Article En | MEDLINE | ID: mdl-27580651

BACKGROUND: Calcium-enriched mixture (CEM) cement is used in the field of endodontics. It is similar to mineral trioxide aggregate in its main ingredients. The present study investigated the effect of different mixing methods on the bacterial microleakage of CEM cement. METHODS: A total of 55 human single-rooted human permanent teeth were decoronated so that 14-mm-long samples were obtained and obturated with AH26 sealer and gutta-percha using lateral condensation technique. Three millimeters of the root end were cut off and randomly divided into 3 groups of 15 each (3 mixing methods of amalgamator, ultrasonic and conventional) and 2 negative and positive control groups (each containing 5 samples). BHI (brain-heart infusion agar) suspension containing Enterococcus faecalis was used for bacterial leakage assessment. Statistical analysis was carried out using descriptive statistics, Kaplan-Meier survival analysis with censored data and log rank test. Statistical significance was set at P<0.05. RESULTS: The survival means for conventional, amalgamator and ultrasonic methods were 62.13±12.44, 68.87±12.79 and 77.53±12.52 days, respectively. The log rank test showed no significant differences between the groups. CONCLUSIONS: Based on the results of the present study it can be concluded that different mixing methods had no significant effect on the bacterial microleakage of CEM cement.


Calcium Compounds/pharmacokinetics , Dental Cements/pharmacokinetics , Dental Leakage/prevention & control , Drug Compounding/methods , Oxides/pharmacokinetics , Phosphorus Compounds/pharmacokinetics , Silicates/pharmacokinetics , Tooth/drug effects , Bismuth , Drug Combinations , Enterococcus faecalis , Epoxy Resins , Gutta-Percha , Humans , In Vitro Techniques , Materials Testing , Nephelometry and Turbidimetry , Powders , Random Allocation , Root Canal Filling Materials , Silver , Titanium , Tooth/microbiology
18.
Expert Opin Drug Metab Toxicol ; 12(5): 567-73, 2016 May.
Article En | MEDLINE | ID: mdl-26998854

INTRODUCTION: Hyperkalemia is a common electrolyte disorder that arises from dysfunctional homeostatic mechanisms or as a consequence of decreased renal function. Sodium zirconium cyclosilicate (ZS-9) is a potential new therapy for hyperkalemia in both acute and chronic settings. AREAS COVERED: Here we discuss mechanisms of potassium homeostasis and preclinical and clinical studies that present pharmacokinetics/pharmacodynamics, efficacy and safety profiles of ZS-9. EXPERT OPINION: ZS-9 has a unique mechanism of action consisting of thermodynamically favorable sequestration of potassium ions, enabling rapid trapping and removal of excess potassium. The potassium lowering action of ZS-9 is predictable and rapid, leading to significant reduction of serum potassium within 1 hour of administration by irreversibly eliminating excess potassium rather than acting via intracellular translocation. Its safety profile, including gastrointestinal events, has been generally similar to that of placebo, with the exception of infrequent but manageable events of peripheral edema and transient hypokalemia. ZS-9 has demonstrated potential for enabling renin-angiotensin-aldosterone system inhibitors in mid-term studies, with long-term studies ongoing.


Hyperkalemia/drug therapy , Potassium/metabolism , Silicates/therapeutic use , Acute Disease , Animals , Chronic Disease , Humans , Hyperkalemia/physiopathology , Renin-Angiotensin System/drug effects , Silicates/pharmacokinetics , Silicates/pharmacology , Time Factors
19.
Sci Rep ; 6: 23422, 2016 Mar 21.
Article En | MEDLINE | ID: mdl-26996657

The present study was performed to determine whether simvastatin improves bone regeneration when combined with calcium silicate/gypsum and gelatin (CS-GEL). The surface morphology was determined using field-emission scanning electron microscopy (FSEM). Degradation in vitro was evaluated by monitoring the weight change of the composites soaked in phosphate buffered saline (PBS). Drug release was evaluated using high-performance liquid chromatography (HPLC). Cytotoxicity testing was performed to assess the biocompatibility of composites. Four 5 mm-diameter bone defects were created in rabbit calvaria. Three sites were filled with CS-GEL, 0.5 mg simvastatin-loaded CS-GEL (SIM-0.5) and 1.0 mg simvastatin-loaded CS-GEL (SIM-1.0), respectively, and the fourth was left empty as the control group. Micro-computed tomography (micro-CT) and histological analysis were carried out at 4 and 12 weeks postoperatively. The composites all exhibited three-dimensional structures and showed the residue with nearly 80% after 4 weeks of immersion. Drug release was explosive on the first day and then the release rate remained stable. The composites did not induce any cytotoxicity. The results in vivo demonstrated that the new bone formation and the expressions of BMP-2, OC and type I collagen were improved in the simvastatin-loaded CS-GEL group. It was concluded that the simvastatin-loaded CS-GEL may improve bone regeneration.


Bone Regeneration/drug effects , Bone Substitutes/administration & dosage , Calcium Compounds/administration & dosage , Calcium Sulfate/administration & dosage , Gelatin/administration & dosage , Silicates/administration & dosage , Simvastatin/administration & dosage , Skull/drug effects , Animals , Bone Substitutes/pharmacokinetics , Calcium Compounds/pharmacokinetics , Calcium Sulfate/pharmacokinetics , Gelatin/pharmacokinetics , Male , Materials Testing , Rabbits , Silicates/pharmacokinetics , Simvastatin/pharmacokinetics , Skull/injuries , Skull/ultrastructure
20.
J Endod ; 42(4): 632-6, 2016 Apr.
Article En | MEDLINE | ID: mdl-26898564

INTRODUCTION: The treatments for which mineral trioxide aggregate (MTA)-based materials can be used in dentistry are expanding. Smaller particle size and easier handling properties have allowed the advent of tricalcium silicate sealers including EndoSequence BC Sealer (Brasseler USA, Savannah, GA), QuickSet2 (Avalon Biomed, Bradenton, FL), NeoMTA Plus (Avalon Biomed), and MTA Fillapex (Angelus, Londrina, Brazil). The objective of this study was to measure the tubule penetration with these sealers using continuous wave (CW) and single-cone (SC) obturation techniques. METHODS: Eighty single-rooted teeth were randomly divided into 8 groups of 10 and obturated with 1 of the previously mentioned sealers mixed with trace amounts of rhodamine using either the CW or SC technique. Teeth were sectioned at 1 mm and 5 mm from the apex and examined under a confocal laser microscope. The percentage of sealer penetration and the maximum sealer penetration were measured. RESULTS: The tricalcium silicate sealers penetrated tubules as deep as 2000 µm (2 mm). The percentage of sealer penetration was much higher 5 mm from the apex, with many specimens having 100% penetration for both SC and warm vertical techniques. MTA Fillapex, a resin-based sealer with less than 20% MTA particles, had significantly greater tubule penetration with a warm vertical technique versus the SC technique at the 1-mm level. CONCLUSIONS: Within the limitations of this study, the CW and SC techniques produced similar tubule penetration at both the 1-mm and the 5-mm level with the tricalcium silicate sealers BC Sealer, QuickSet2, and NeoMTA Plus.


Aluminum Compounds/pharmacokinetics , Calcium Compounds/pharmacokinetics , Dentin/metabolism , Oxides/pharmacokinetics , Root Canal Filling Materials/pharmacokinetics , Silicates/pharmacokinetics , Zinc Oxide-Eugenol Cement/pharmacokinetics , Aluminum Compounds/pharmacology , Calcium Compounds/pharmacology , Dentin/anatomy & histology , Dentin/drug effects , Drug Combinations , Humans , Oxides/pharmacology , Random Allocation , Root Canal Filling Materials/pharmacology , Root Canal Irrigants/pharmacokinetics , Root Canal Irrigants/pharmacology , Root Canal Obturation/methods , Root Canal Preparation/instrumentation , Root Canal Preparation/methods , Silicates/pharmacology , Tooth/metabolism , Tooth Apex/anatomy & histology , Tooth Apex/drug effects , Tooth Apex/metabolism , Zinc Oxide-Eugenol Cement/pharmacology
...